<DOC>
	<DOCNO>NCT02891824</DOCNO>
	<brief_summary>This phase III , randomize , double-blinded , comparative , multi-centre study ass efficacy atezolizumab combination platinum-based chemotherapy plus bevacizumab administer concurrent chemotherapy maintenance , patient present epithelial ovarian cancer ( include patient primary peritoneal / fallopian tube adenocarcinoma ) platinum-sensitive relapse ( platinum-free interval &gt; 6 month ) .</brief_summary>
	<brief_title>ATALANTE : Atezolizumab v Placebo Phase III Study Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab</brief_title>
	<detailed_description>Approximately 405 patient randomize use Interactive Voice Response System /Interactive web system ( IVR/IWR system ) 1:2 ratio treatment specify : A . Arm A : Placebo + bevacizumab &amp; platinum-based chemotherapy . The placebo arm include one 3 follow regimen investigator choice ( choose prior randomization ) 1 . Carboplatin ( day1 ) combine gemcitabine ( day1 &amp; day8 ) bevacizumab ( day1 ) + placebo ( day1 ) x 6 cycle q3weeks follow maintenance bevacizumab ( day1 ) + placebo ( day1 ) q3weeks disease progression 2 . Carboplatin ( d1 ) combine paclitaxel ( day1 ) bevacizumab ( day1 ) + placebo ( d1 ) x 6 cycle every 3weeks follow maintenance bevacizumab ( day1 ) + placebo ( day1 ) q3weeks disease progression 3 . Carboplatin ( day1 ) combine pegylated liposomal doxorubicin ( PLD ) ( day1 ) bevacizumab ( day1 &amp; 15 ) + placebo ( day1 &amp; 15 ) x 6 cycle every 4weeks follow maintenance bevacizumab ( day1 ) + placebo ( day1 ) q3weeks disease progression . B . Arm B : Atezolizumab + bevacizumab &amp; platinum-based chemotherapy The atezolizumab arm include one 3 follow regimen investigator choice ( choose prior randomization ) 1 . Carboplatin ( day1 ) combine gemcitabine ( day1 &amp; d8 ) bevacizumab ( day1 ) + atezolizumab ( day1 ) x 6 cycle q3weeks follow maintenance bevacizumab ( day1 ) + atezolizumab ( day1 ) q3w disease progression 2 . Carboplatin ( day1 ) combine paclitaxel ( day1 ) bevacizumab ( day1 ) + atezolizumab ( 1200mg , d1 ) x 6 cycle every 3wk ( day1 ) q3weeks disease progression 3 . Carboplatin ( day1 ) combine pegylated liposomal doxorubicin ( PLD ) ( day1 ) bevacizumab ( day1 &amp; 15 ) + atezolizumab ( day1 &amp; 15 ) x 6 cycle every 4weeks follow maintenance bevacizumab ( day1 ) + atezolizumab ( day1 ) q3weeks disease progression . Before randomization study : - A tumor biopsy obtain sent central laboratory - PD-L1 status determine</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Female Patients must ≥18 year age . 2 . Signed informed consent ability comply treatment followup . 3 . Patients histologically confirm progressive nonmucinous epithelial ovarian cancer , primary peritoneal adenocarcinoma / fallopiantube adenocarcinoma 4 . Patients PDL1 status determine stratification mandatory de novo biopsy send central laboratory formalinfixed , paraffinembedded ( FFPE ) sample . Cell pellet pleural effusion , ascites lavage acceptable . For core needle biopsy specimen , least three core obtain . Biopsies must obtain manner minimizes risk . If location tumor render tumor biopsy medically unsafe feasible , patient eligibility discuss sponsor . 5 . Patients whose disease relapse 6 month last dose platinum randomization : 1. criterion relapse accord RECIST v1.1 , CA125 ( GCIG ) clinical symptom 2. interval last dose platinum entry study free new anticancer treatment , exception maintenance therapy allow 21 day study entry . 6 . Patients one 2 prior line chemotherapy . The last line chemotherapy include platinum . 7 . Availability study site representative FFPE tumor sample surgery front line therapy , best chemotherapy 8 . Patients must normal organ bone marrow function : 1 . Haemoglobin ≥ 10.0 g/dL . 2 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L . 3 . Platelet count ≥ 100 x 109/L . 4 . Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) . 5 . Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase ( ASAT/SGOT ) ) Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase ( ALAT/SGPT ) ) ≤ 2.5 x ULN , unless liver metastasis present case must ≤ 5 x ULN . 6 . Serum creatinine ≤ 1.5 x institutional ULN , 7 . Patients receive anticoagulant medication International Normalized Ratio ( INR ) ≤1.5 Activated ProThrombin Time ( aPTT ) ≤1.5 x ULN . The use fulldose oral parenteral anticoagulant permit long INR APTT within therapeutic limit ( accord site medical standard ) patient stable dose anticoagulant least two week time randomization . 8 . Urine dipstick proteinuria &lt; 2+ . If urine dipstick ≥2+ , 24hours urine must demonstrate ≤1 g protein 24 hour . 9 . Normal blood pressure adequately treat controlled hypertension ( systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg ) . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 For France : In France , subject eligible randomization study either affiliate , beneficiary , social security category 1 . Nonepithelial tumor origin ovary , fallopian tube peritoneum ( i.e . germ cell tumor ) . 2 . Ovarian tumor low malignant potential ( e.g . borderline tumor ) 3 . Patients synchronous primary endometrial cancer unless follow criterion meet : 1. stage &lt; II , 2 . Less 60 year old time diagnosis endometrial cancer stage IA IB grade 1 2 , stage IA grade 3 endometrioid adenocarcinoma OR ≥ 60 year old time diagnosis endometrial cancer stage IA grade 1or 2 endometrioid adenocarcinoma . 3 . Patients serous clear cell adenocarcinoma carcinosarcoma endometrium eligible . 4 . Other malignancy within last 5 year except cervix breast situ carcinoma , breast cancer ≥ 3 year free disease treatment , type I stage I endometrial cancer ) . 5 . Patients receive radiotherapy within 6 week prior study treatment . 6 . Major surgery within 4 week start study treatment patient completely recover effect major surgery . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 , Cycle 1 7 . Previous allogeneic bone marrow transplant previous solid organ transplantation . 8 . Administration simultaneous chemotherapy drug , anticancer therapy antineoplastic hormonal therapy , simultaneous radiotherapy trial treatment period ( hormonal replacement therapy permit ) . 9 . Prior treatment CD137 agonists immune checkpoint blockade therapy , anti−PD1 , anti−PDL1 therapeutic antibody antiCTLA 4 . 10 . Treatment systemic immunostimulatory agent ( include limit interferonalpha ( IFNα ) interleukin2 ( IL2 ) within 4 week five halflives drug ( whichever short ) prior Cycle 1 , Day 1 11 . Treatment systemic corticosteroid systemic immunosuppressive medication ( include limit prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , anti−tumor necrosis factor [ TNF ] agent ) within 2 week prior Cycle 1 , Day 1 , anticipate requirement systemic immunosuppressive medication trial 1 . The use inhale corticosteroid chronic obstructive pulmonary disease , mineralocorticoid ( e.g. , fludrocortisone ) patient orthostatic hypotension , lowdose supplemental corticosteroid adrenocortical insufficiency allow . 2 . Prophylactic antiemetic corticosteroid avoid possible patient treat pegylated liposomal doxorubicincarboplatin gemcitabinecarboplatin regimen . The use corticosteroid allow premedication paclitaxelbased regimen and/or premedication case carboplatin hypersensitivity . 12 . History autoimmune disease , include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis . Are eligible patient : 1. history autoimmune hypothyroidism stable dose thyroid replacement hormone 2. control Type 1 diabetes mellitus stable insulin regimen 13 . History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia ) , evidence active pneumonitis . Radiation pneumonitis radiation field ( fibrosis ) detect screen chest CT scan permit 14 . Immunocompromised patient , e.g. , patient know serologically positive human immunodeficiency virus ( HIV ) . Patients active hepatitis B ( define positive hepatitis B surface antigen [ HBsAg ] test screening ) hepatitis C. Patients past hepatitis B virus ( HBV ) infection resolve HBV infection ( define negative HBsAg test positive antibody hepatitis B core antigen [ antiHBc ] antibody test ) eligible Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV RNA . 15 . Signs symptoms infection within 2 week prior Cycle 1 , Day 1 16 . Administration live , attenuated vaccine within 4 week prior Cycle 1 , Day 1 anticipation live attenuated vaccine require study . Influenza vaccination give influenza season ( example approximately October March Northern Hemisphere ) . Patients must receive live , attenuate influenza 17 . Current recent ( within 10 day prior randomization ) chronic use aspirin &gt; 325 mg/day . 18 . Prior history hypertensive crisis ( CTCAE grade 4 ) hypertensive encephalopathy . 19 . Inadequately control HTN ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) 20 . Clinically significant ( e.g . active ) cardiovascular disease , include : 1 . Myocardial infarction unstable angina within ≤ 6 month randomization , 2 . New York Heart Association ( NYHA ) ≥ grade 2 congestive heart failure ( CHF ) , 3 . Poorly control cardiac arrhythmia despite medication ( patient rate control atrial fibrillation eligible ) , 4 . Peripheral vascular disease grade ≥ 3 ( e.g . symptomatic interfering activity daily live [ ADL ] require repair revision ) 21 . Resting ECG QTc &gt; 470 msec 2 time point within 24 hour period family history long QT syndrome . 22 . Left ventricular ejection fraction define MUGA/ECHO institutional low limit normal ( applicable patient intend treat pegylated liposomal doxorubicin ) . 23 . Previous CerebroVascular Accident ( CVA ) , Transient Ischemic Attack ( TIA ) SubArachnoids Hemorrhage ( SAH ) within 6 month prior randomization . 24 . History evidence hemorrhagic disorder within 6 month prior randomization . 25 . Evidence bleed diathesis significant coagulopathy ( absence coagulation ) . 26 . History clinical suspicion brain metastasis spinal cord compression . CT/MRI brain mandatory ( within 4 week prior randomization ) case suspect brain metastasis . Spinal MRI mandatory ( within 4 week prior randomization ) case suspect spinal cord compression . 27 . History evidence upon neurological examination central nervous system ( CNS ) disease , unless adequately treat standard medical therapy ( e.g . uncontrolled seizure ) . 28 . Significant traumatic injury 4 week prior randomization . 29 . Nonhealing wound , active ulcer bone fracture . Patients granulate incision heal secondary intention evidence facial dehiscence infection eligible require 3 weekly wound examination . 30 . History VEGF therapy relate abdominal fistula gastrointestinal perforation . 31 . Current , clinically relevant bowel obstruction , include subocclusive disease , relate underlying disease . 32 . Patients evidence abdominal free air explain paracentesis recent surgical procedure . 33 . Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatment related complication . 34 . Women childbearing potential ( &lt; 2 year last menstruation surgically sterile ) willing use highlyeffective mean contraception ( Appendix 1 ) study 6 month last dose study medication 35 . Pregnant lactating woman . 36 . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein . 37 . Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation . 38 . Known hypersensitivity reaction allergy drug chemically relate bevacizumab , carboplatin , gemcitabine , paclitaxel , pegylated liposomal doxorubicin , excipients contraindicate subject 's participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PD-L1</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>Randomized , double blind</keyword>
	<keyword>first second late relapse</keyword>
	<keyword>progressive non-mucinous epithelial ovarian cancer , primary peritoneal adenocarcinoma / fallopian-tube adenocarcinoma</keyword>
	<keyword>progression-free survival</keyword>
</DOC>